[91290] in SIPB IPv6
This year, every pot-stock will double-in value: Rep. 787720061
daemon@ATHENA.MIT.EDU (Aidan Lucas)
Tue May 16 17:01:58 2017
Date: Tue, 16 May 2017 16:53:58 -0400
From: "Aidan Lucas" <aidan-lucas@tekteksese.com>
To: <sipbv6-mtg@charon2.mit.edu>
Marijuana-Legalization Update
May 16, 2016
As more states legalized-the once banned product this year- the value has gone up like crazy ever since.
http://www.tekteksese.com/tonight-Harbin/4eH8tx6g455v7bOnvkLX-dhVtFMuKmji10hvV0ONW9f8
Industry experts say that next-year they will be worth a-fortune and there is no better time than now to get in on the action.
Amanda Atwood, has already made everything back and then some.
Full Story: Get In Now >
http://www.tekteksese.com/tonight-Harbin/4eH8tx6g455v7bOnvkLX-dhVtFMuKmji10hvV0ONW9f8
Easy to let go, just tell us in here:
http://www.tekteksese.com/ontology-veering/a0886-E45p6Al7brnvkLX-dhVtFMuKmji10hvV0ONWbbb
PO Box 16580 #22445 Baltimore, MD 21217
You can always stop receiving this, if you follow the following page
http://www.tekteksese.com/9cb89uxPg457Uj7bQnvkLX-dhVtFMuKmji10hvV0ONW4f0/shooters-deferrable
James Nieland ^ 71 Rolling Hills Rd Williamsburg Ky 40769-8776
Insys isn't your typical marijuana stock. It doesn't devote its entire drug-development pipeline to discovering cannabinoid-based drugs. For years, its foundation has been built on a sublingual breakthrough cancer pain drug known as Subsys, which more or less accounts for all of its revenue at the moment.
Insys' most recent issues stem from allegations and lawsuits that a majority of Subsys prescriptions were being written for off-label use. As a result, Insys has seen sales of its core product halved from more than $300 million on a trailing 12-month basis in 2015 to a Street expectation of $163 million in sales in 2017. Insys is also projected to lose money in 2017, per Wall Street's consensus.
What could change all this is the impending launch of Syndros in the second-half of 2017. Syndros is an oral dronabinol solution, which is essentially a pharmaceutical version of tetrahydrocannabinol (THC), the psychoactive component of cannabis. It was approved by the Food and Drug Administration (FDA) last year as a treatment for chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with AIDS, but it took months for the Drug Enforcement Agency to schedule the drug. With a schedule II status now reached, Insys is preparing for its launch.
According to Wall Street's estimates, Syndros has the potential to hit $300 million to $400 million in peak annual sales, which is around what Subsys was generating at its peak. The big question mark is whether Syndros is going to be able to successfully navigate a very crowded CINV market. If it can, and Subsys' sales stabilize, Insys could see its sales more than double over the next three years, with annual EPS approaching $1 by 2020. This would make Insys quite an undervalued marijuana stock.
